The median percentage of viable tumor in resected patients without known tumor EGFR/ALK alterations was 51% (range 0–95.5%) in the Nivo+CT arm (n = 17) compared with 2.8% (range 0–94.4%) in the Ipi+Nivo+CT arm (n = 14) (Fig. 2d). The gene discussed is EGFR; the disease is neoplasm.